Levosimendan protects against ischemia – reperfusion injury in the human heart muscle. A pilot study
The consequences of myocardial infarction (MI) are an increasing problem worldwide. Despite spectacular progress in the invasive treatment of ischemic heart disease, the ability to limit the ischemia-reperfusion (I/R) injury remains largely unrealized. Recent studies have shown that stimulation of o...
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Sciendo
2022-12-01
|
| Series: | Current Issues in Pharmacy and Medical Sciences |
| Subjects: | |
| Online Access: | https://doi.org/10.2478/cipms-2022-0038 |
| _version_ | 1827998171326840832 |
|---|---|
| author | Kunecki Marcin Oleksy Tomasz Nozynski Jerzy Podolec Piotr Biernat Jolanta Deja Marek Andrzej Golba Krzysztof Stanislaw Plazak Wojciech |
| author_facet | Kunecki Marcin Oleksy Tomasz Nozynski Jerzy Podolec Piotr Biernat Jolanta Deja Marek Andrzej Golba Krzysztof Stanislaw Plazak Wojciech |
| author_sort | Kunecki Marcin |
| collection | DOAJ |
| description | The consequences of myocardial infarction (MI) are an increasing problem worldwide. Despite spectacular progress in the invasive treatment of ischemic heart disease, the ability to limit the ischemia-reperfusion (I/R) injury remains largely unrealized. Recent studies have shown that stimulation of opioid receptors may confer a cardioprotective effect against I/R injury. Levosimendan, the inodilator, is indicated for the short-term treatment of acutely decompensated heart failure. We tested the hypothesis that levosimendan may provide cardioprotection in the opioid-like mechanism in the human myocardium. |
| first_indexed | 2024-04-10T05:39:36Z |
| format | Article |
| id | doaj.art-1d059496d9cf452c860b8e82f1d2bc51 |
| institution | Directory Open Access Journal |
| issn | 2300-6676 |
| language | English |
| last_indexed | 2024-04-10T05:39:36Z |
| publishDate | 2022-12-01 |
| publisher | Sciendo |
| record_format | Article |
| series | Current Issues in Pharmacy and Medical Sciences |
| spelling | doaj.art-1d059496d9cf452c860b8e82f1d2bc512023-03-06T10:29:55ZengSciendoCurrent Issues in Pharmacy and Medical Sciences2300-66762022-12-0135421922310.2478/cipms-2022-0038Levosimendan protects against ischemia – reperfusion injury in the human heart muscle. A pilot studyKunecki Marcin0Oleksy Tomasz1Nozynski Jerzy2Podolec Piotr3Biernat Jolanta4Deja Marek Andrzej5Golba Krzysztof Stanislaw6Plazak Wojciech7Department of Electrocardiology and Heart Failure, Medical University of Silesia, Katowice, PolandDepartment of Electrocardiology and Heart Failure, Medical University of Silesia, Katowice, PolandDepartment of Histology and Embryology, Medical University of Silesia, Katowice, PolandDepartment of Cardiac and Vascular Diseases, John Paul II Hospital, Jagiellonian University Medical College, Kraków, PolandDepartment of Electrocardiology and Heart Failure, Medical University of Silesia, Katowice, PolandDepartment of Cardiac Surgery, Medical University of Silesia, Katowice, PolandDepartment of Electrocardiology and Heart Failure, Medical University of Silesia, Katowice, PolandDepartment of Cardiac and Vascular Diseases John Paul II Hospital, Jagiellonian University Medical College, Kraków, PolandThe consequences of myocardial infarction (MI) are an increasing problem worldwide. Despite spectacular progress in the invasive treatment of ischemic heart disease, the ability to limit the ischemia-reperfusion (I/R) injury remains largely unrealized. Recent studies have shown that stimulation of opioid receptors may confer a cardioprotective effect against I/R injury. Levosimendan, the inodilator, is indicated for the short-term treatment of acutely decompensated heart failure. We tested the hypothesis that levosimendan may provide cardioprotection in the opioid-like mechanism in the human myocardium.https://doi.org/10.2478/cipms-2022-0038ischemiareperfusionlevosimendanmorphology of micardioprotection |
| spellingShingle | Kunecki Marcin Oleksy Tomasz Nozynski Jerzy Podolec Piotr Biernat Jolanta Deja Marek Andrzej Golba Krzysztof Stanislaw Plazak Wojciech Levosimendan protects against ischemia – reperfusion injury in the human heart muscle. A pilot study Current Issues in Pharmacy and Medical Sciences ischemia reperfusion levosimendan morphology of mi cardioprotection |
| title | Levosimendan protects against ischemia – reperfusion injury in the human heart muscle. A pilot study |
| title_full | Levosimendan protects against ischemia – reperfusion injury in the human heart muscle. A pilot study |
| title_fullStr | Levosimendan protects against ischemia – reperfusion injury in the human heart muscle. A pilot study |
| title_full_unstemmed | Levosimendan protects against ischemia – reperfusion injury in the human heart muscle. A pilot study |
| title_short | Levosimendan protects against ischemia – reperfusion injury in the human heart muscle. A pilot study |
| title_sort | levosimendan protects against ischemia reperfusion injury in the human heart muscle a pilot study |
| topic | ischemia reperfusion levosimendan morphology of mi cardioprotection |
| url | https://doi.org/10.2478/cipms-2022-0038 |
| work_keys_str_mv | AT kuneckimarcin levosimendanprotectsagainstischemiareperfusioninjuryinthehumanheartmuscleapilotstudy AT oleksytomasz levosimendanprotectsagainstischemiareperfusioninjuryinthehumanheartmuscleapilotstudy AT nozynskijerzy levosimendanprotectsagainstischemiareperfusioninjuryinthehumanheartmuscleapilotstudy AT podolecpiotr levosimendanprotectsagainstischemiareperfusioninjuryinthehumanheartmuscleapilotstudy AT biernatjolanta levosimendanprotectsagainstischemiareperfusioninjuryinthehumanheartmuscleapilotstudy AT dejamarekandrzej levosimendanprotectsagainstischemiareperfusioninjuryinthehumanheartmuscleapilotstudy AT golbakrzysztofstanislaw levosimendanprotectsagainstischemiareperfusioninjuryinthehumanheartmuscleapilotstudy AT plazakwojciech levosimendanprotectsagainstischemiareperfusioninjuryinthehumanheartmuscleapilotstudy |